Anhang zu „Medizinische Empfehlungen für substitutionsgestützte Behandlungen (SGB) bei Opioidabhängigkeit“

Referenzen


2. Ritonavir (Norvir) and methadone. Treat Rev 1998; (No 28):15


14. Al-Khatib SM, LaPointe NM, Kramer JM, Califf RM. What clinicians should know about the QT interval. JAMA 2003; 289(16):2120-7


33. Andersen HT. Regelmessig forskrivning av A- og B-preparater til rusavhengige i allmennpraksis [Regular prescription of narcotics and sedatives to drug-addicted patients in general practice]. Tidsskr Nor Laegeforen 2002; 122(12):1202-4


50. Avants SK, Margolin A, Kosten TR, Rounsaville BJ, Schottenfeld RS. When is less treatment better? The role of social anxiety in matching methadone patients to psychosocial treatments. Journal of consulting and clinical psychology 1998; 66:924-31


55. Ball JC, Ross A. The Effectiveness of Methadone Maintenance Treatment: Patients, Programs, Services, and Outcome. Springer; 1991.


84. Bennett J, Whale R. Galactorrhoea may be associated with methadone use. BMJ 2006; 332(7549):1071


88. Bergschmidt VB. Pleasure, power and dangerous substances: applying Foucault to the study of 'heroin dependence' in Germany. Anthropology-and-medicine 2004; 11(1):59-74


90. Bertisch B, Meili D, Huber M. Nachweis von Hepatitis-C-Viruslast in gebrauchten Heroinspritzen. Suchttherapie 2002; Sup 1


93. Bickel WK, Amass L, Crean JP, Badger GJ. Buprenorphine dosing every 1, 2, or 3 days in opioid-dependent patients. Psychopharmacology (Berl) 1999; 146(2):111-8


101. Boissonnas A. [How to treat a patient with AIDS and drug dependence unwilling and/or unable to withdraw? Give substitution drugs at the hospital? Should substitution be continued after discharge? Is substitution a useful adjuvant to programs designed to prevent opportunistic diseases?] opportunisticinfections]. Ann Med Interne (Paris) 1994; 145(Suppl 3):54-5


125. Buster MCA, Brussel GHA, van den Brink W. An increase in overdose mortality during the first 2 weeks after entering or re-entering methadone treatment in Amsterdam. Addiction 2002; 97(8):993-1001


182. Comer SD, Collins ED, Fischman MW. Intravenous buprenorphine self-administration by detoxified heroin abusers. J Pharmacol Exp Ther 2002; 301(1):266-76


262. Donny EC, Brasser SM, Bigelow GE, Stitzer ML, Walsh SL. Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 2005; 100(10):1496-509


266. Douglas SD. Methadone may promote HIV replication: study. AIDS Alert 2001; 16(9):120


270. Dressler FA, Roberts WC. Modes of death and types of cardiac diseases in opiate addicts: analysis of 168 necropsy cases. Am J Cardiol 1989; 64(14):909-20


291. el Bassel N, Chen DR, Cooper D. Social support and social network profiles among women on methadone. Social-service-review 1998; 72(3):379-401


347. Gerstein DR. Cultural action and heroin addiction. Sociol Inq 1981; 51(3-4):355-70


21


373. Gourevitch MN, Friedland GH. Methadone and antiretroviral medications, part II. AIDS Clin Care 1999; 11(5):37, 43, 45-37, 43, 46


411. Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost effectiveness of buprenorphine as an alternative to methadone maintenance treatment for heroin dependence in a primary care setting. PharmacoEconomics 2005; 23:77-91


418. Heilig M, Kakko J. Dämpat drogsuch och bättre social funktion med buprenorfinterapi. Kombinationsbehandling alternativ till metodon vid heroinmissbruk [Reduced drug craving and better social function with buprenorphine therapy. Combination therapy as an alternative to methadone therapy in heroin addiction]. Lakartidningen 2003; 100(32-33):2526-7


507. Kissin W, McLeod C, Sonnfeld J, Stanton A. Experiences of a national sample of qualified addiction specialists who have and have not prescribed buprenorphine for opioid dependence. J Addict Dis 2006; 25(4):91-103


544. Krook AL, Waal H, Hansteen V. EKG som routine for metadonassisterd rehabilitering er feil prioritering [Routine ECG in methadone-assisted rehabilitation is wrong prioritization]. Tidsskr Nor Laegeforen 2004; 124(22):2940-1


564. Lejeune C, Simmat-Durand L, Gourarier L, Aubisson S. Prospective multicenter observational study of 260 infants born to 259 opiate-dependent mothers on methadone or high-dose buprenophine substitution. Drug Alcohol Depend 2006; 82(3):250-7


582. Lofwall MR, Strain EC, Sitzer ML, Bigelow GE. Comparative safety and side-effect profiles of buprenorphine vs. methadone in the outpatient treatment of opioid dependence. Sixty Sixth Annual Scientific Meeting of College on Problems of Drug Dependence 2004;


671. Montagne M. Appreciating the user's perspective: listening to the "methadonians". Subst Use Misuse 2002; 37(4):565-70


675. Moral MP, Rueda SJ, Tasias PM, Calbuig Jr. [Torsade de Pointes in patient infected with human immunodeficiency virus and treated with methadone]. An Med Interna 2006; 23(8):397-8


Ref Type: Generic


690. New York State Department of Health Al. Drug-Drug Interactions Between HAART, Medications Used in Substance Use Treatment, and Recreational Drugs. 2005. Ref Type: Generic


713. Pasternak GW. Multiple opiate receptors: deja vu all over again. Neuropharmacology 2004; 47 Suppl 1:312-23


762. Raisch DW, Fye CL, Boardman KD, Sather MR. Opioid dependence treatment, including buprenorphine/naloxone. Ann Pharmacother 2002; 36(2):312-21


780. Riker RR, Fraser GL. Adverse events associated with sedatives, analgesics, and other drugs that provide patient comfort in the intensive care unit. Pharmacotherapy 2005; 25(s Pt 2):85-185


785. Robinson SE. Buprenorphine-containing treatments: place in the management of opioid addiction. CNS Drugs 2006; 20(9):697-712


810. Schiff M, Levit S, Moreno RC. Retention and illicit drug use among methadone patients in Israel: A gender comparison. Addict Behav 2007;


815. Scholz M. Managing constipation that's opioid-induced. RN 2000; 63(6):103


821. Schuster CR. History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs. Drug Alcohol Depend 2006; 83 Suppl 1:S8-S14


830. Seivewright N, Iqbal MZ. Prescribing to drug misusers in practice—often effective, but rarely straightforward. Addict Biol 2002; 7(3):269-77


911. Tzschentke TM. Behavioral pharmacology of buprenorphine, with a focus on preclinical models of reward and addiction. Psychopharmacology (Berl) 2002; 161(1):1-16


924. van Beusekom IJ, Iguchi MY. A Review of Recent Advances in Knowledge About Methadone Maintenance Treatment. RAND Corporation Europe; 2001.


929. van Haastrecht HJ, Bax JS, van den Hoek AA. High rates of drug use, but low rates of HIV risk behaviours among injecting drug users during incarceration in Dutch prisons. Addiction 1998; 93(9):1417-25


957. Wang J, Ruan Y, Taylor RM, Donovan JL, Markowitz JS, DeVane CL. Brain penetration of methadone (R)- and (S)-enantiomers is greatly increased by P-glycoprotein deficiency in the blood-brain barrier of Abcb1a gene knockout mice. Psychopharmacology (Berl) 2004; 173(1-2):132-8


964. Weig W. Migration und seelische Gesundheit. IMIS-Beiträge 1998; (8):31-44


974. Wilczek H, Stepan J. [Bone metabolism in individuals dependent on heroin and after methadone administration]. Cas Lek Cesk 2003; 142(10):606-8


977. Wittchen HU, Perkonigg A, Reed V. Comorbidity of Mental Disorders and Substance Use Disorders. Eur Addict Res 1996; 2:36-47


989. Yuan CS, Foss JF, O’Connor M, Osinski J, Karrison T, Moss J, Roizen MF. Methylaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 2000; 283(3):367-72


996. Zacny JP. Characterizing the subjective, psychomotor, and physiological effects of a hydrocodone combination product (Hycodan) in non-drug-abusing volunteers. Psychopharmacology (Berl) 2003; 165(2):146-56


